- 抑制劑
- 研究領(lǐng)域
- PI3K/Akt/mTOR信號(hào)通路
- 表觀遺傳
- 甲基化
- 免疫&炎癥
- 酪氨酸蛋白激酶
- 血管生成
- 凋亡
- 自噬
- 內(nèi)質(zhì)網(wǎng)應(yīng)激&UPR響應(yīng)
- JAK/STAT信號(hào)通路
- MAPK信號(hào)通路
- 細(xì)胞骨架
- 細(xì)胞周期
- TGF-beta/Smad信號(hào)通路
- DNA損傷/DNA修復(fù)
- 化合物庫(kù)
- 抗體
- 生物試劑
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- 蛋白實(shí)驗(yàn)
- Protein A/G免疫沉淀磁珠
- Anti-DYKDDDDK Tag免疫磁珠
- Anti-DYKDDDDK Tag親和凝膠
- Anti-Myc免疫磁珠
- Anti-HA免疫磁珠
- 磁力架
- Poly DYKDDDDK Tag多肽
- 蛋白酶抑制劑Cocktail
- 蛋白酶抑制劑Cocktail(DMSO儲(chǔ)液)
- 磷酸酶抑制劑Cocktail
- 細(xì)胞實(shí)驗(yàn)
- Cell Counting Kit-8 (CCK-8)
- 動(dòng)物實(shí)驗(yàn)
- 鼠尾直接PCR試劑盒(快速基因型鑒定)
- 小鼠CD3+ T細(xì)胞分選試劑盒
- 小鼠CD4+ T細(xì)胞分選試劑盒
- 小鼠CD8+ T細(xì)胞分選試劑盒
- 新產(chǎn)品
- 聯(lián)系我們
JNK Inhibitor VIII
別名: TCS?JNK?6o 中文名稱：JNK抑制劑8
JNK Inhibitor VIII (TCS JNK 6o) 是一種 c-Jun N-terminal kinases 的抑制劑，對(duì)JNK-1和JNK-2的IC50值分別為45 nM和160 nM。JNK Inhibitor VIII (TCS JNK 6o) 可抑制JNK-1、JNK-2和JNK-3，對(duì)應(yīng)的Ki值分別為2 nM、4 nM和52 nM。
JNK Inhibitor VIII Chemical Structure
CAS: 894804-07-0
產(chǎn)品質(zhì)控
批次：
S779401
DMSO]71 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false
純度：
99.77%
99.77
JNK Inhibitor VIII相關(guān)產(chǎn)品
| 相關(guān)靶點(diǎn) | JNK1 JNK2 JNK3 | 點(diǎn)擊展開 |
|---|---|---|
| 相關(guān)產(chǎn)品 | SP600125 JNK-IN-8 Anisomycin JNK Inhibitor IX Tanzisertib HCl(CC-930) Bentamapimod (AS602801) BI-78D3 SP 600125, negative control DTP3 CC-401 Hydrochloride Polyphyllin I | 點(diǎn)擊展開 |
| 相關(guān)化合物庫(kù) | 激酶抑制劑庫(kù) MAPK抑制劑庫(kù) 細(xì)胞周期化合物庫(kù) TGF-beta/Smad信號(hào)通路庫(kù) 抗阿爾茨海默病化合物庫(kù) | 點(diǎn)擊展開 |
相關(guān)信號(hào)通路圖
細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例
| 細(xì)胞系 | 實(shí)驗(yàn)類型 | 給藥濃度 | 孵育時(shí)間 | 活性描述 | 文獻(xiàn)信息 |
|---|---|---|---|---|---|
| NB7 | Growth inhibition assay | Inhibition of human NB7 cell growth in a cell viability assay, IC50=2.27473μM | SANGER | ||
| LB2241-RCC | Growth inhibition assay | Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50=6.57739μM | SANGER | ||
| NCI-H1299 | Growth inhibition assay | Inhibition of human NCI-H1299 cell growth in a cell viability assay, IC50=13.2019μM | SANGER | ||
| BV-173 | Growth inhibition assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50=14.0505μM | SANGER | ||
| HPAF-II | Growth inhibition assay | Inhibition of human HPAF-II cell growth in a cell viability assay, IC50=14.5873μM | SANGER | ||
| RS4-11 | Growth inhibition assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50=16.6795μM | SANGER | ||
| EW-1 | Growth inhibition assay | Inhibition of human EW-1 cell growth in a cell viability assay, IC50=17.1883μM | SANGER | ||
| NCI-H1581 | Growth inhibition assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50=17.2588μM | SANGER | ||
| SK-PN-DW | Growth inhibition assay | Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50=17.9485μM | SANGER | ||
| KP-4 | Growth inhibition assay | Inhibition of human KP-4 cell growth in a cell viability assay, IC50=19.1087μM | SANGER | ||
| DU-145 | Growth inhibition assay | Inhibition of human DU-145 cell growth in a cell viability assay, IC50=19.8748μM | SANGER | ||
| ACHN | Growth inhibition assay | Inhibition of human ACHN cell growth in a cell viability assay, IC50=20.6213μM | SANGER | ||
| A172 | Growth inhibition assay | Inhibition of human A172 cell growth in a cell viability assay, IC50=21.263μM | SANGER | ||
| HuO-3N1 | Growth inhibition assay | Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50=21.4318μM | SANGER | ||
| QIMR-WIL | Growth inhibition assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50=22.3274μM | SANGER | ||
| NCI-H1650 | Growth inhibition assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50=22.7873μM | SANGER | ||
| SW1088 | Growth inhibition assay | Inhibition of human SW1088 cell growth in a cell viability assay, IC50=23.1641μM | SANGER | ||
| Mewo | Growth inhibition assay | Inhibition of human Mewo cell growth in a cell viability assay, IC50=23.3997μM | SANGER | ||
| NCI-H1355 | Growth inhibition assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50=24.6365μM | SANGER | ||
| SK-LU-1 | Growth inhibition assay | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50=27.058μM | SANGER | ||
| KYSE-70 | Growth inhibition assay | Inhibition of human KYSE-70 cell growth in a cell viability assay, IC50=27.125μM | SANGER | ||
| KP-N-YS | Growth inhibition assay | Inhibition of human KP-N-YS cell growth in a cell viability assay, IC50=27.5706μM | SANGER | ||
| HTC-C3 | Growth inhibition assay | Inhibition of human HTC-C3 cell growth in a cell viability assay, IC50=27.7345μM | SANGER | ||
| NB17 | Growth inhibition assay | Inhibition of human NB17 cell growth in a cell viability assay, IC50=27.9113μM | SANGER | ||
| GOTO | Growth inhibition assay | Inhibition of human GOTO cell growth in a cell viability assay, IC50=27.9415μM | SANGER | ||
| BEN | Growth inhibition assay | Inhibition of human BEN cell growth in a cell viability assay, IC50=29.865μM | SANGER | ||
| HMV-II | Growth inhibition assay | Inhibition of human HMV-II cell growth in a cell viability assay, IC50=30.1553μM | SANGER | ||
| SF295 | Growth inhibition assay | Inhibition of human SF295 cell growth in a cell viability assay, IC50=32.156μM | SANGER | ||
| MPP-89 | Growth inhibition assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50=33.5199μM | SANGER | ||
| LCLC-103H | Growth inhibition assay | Inhibition of human LCLC-103H cell growth in a cell viability assay, IC50=34.2223μM | SANGER | ||
| MN-60 | Growth inhibition assay | Inhibition of human MN-60 cell growth in a cell viability assay, IC50=36.0139μM | SANGER | ||
| BB65-RCC | Growth inhibition assay | Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50=36.1528μM | SANGER | ||
| BHY | Growth inhibition assay | Inhibition of human BHY cell growth in a cell viability assay, IC50=36.9645μM | SANGER | ||
| SK-MEL-3 | Growth inhibition assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50=37.7324μM | SANGER | ||
| NY | Growth inhibition assay | Inhibition of human NY cell growth in a cell viability assay, IC50=37.7592μM | SANGER | ||
| CAL-72 | Growth inhibition assay | Inhibition of human CAL-72 cell growth in a cell viability assay, IC50=37.9289μM | SANGER | ||
| ES3 | Growth inhibition assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50=38.1949μM | SANGER | ||
| NBsusSR | Growth inhibition assay | Inhibition of human NBsusSR cell growth in a cell viability assay, IC50=39.3132μM | SANGER | ||
| NB10 | Growth inhibition assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50=40.1731μM | SANGER | ||
| ChaGo-K-1 | Growth inhibition assay | Inhibition of human ChaGo-K-1 cell growth in a cell viability assay, IC50=41.1576μM | SANGER | ||
| KYSE-450 | Growth inhibition assay | Inhibition of human KYSE-450 cell growth in a cell viability assay, IC50=41.4514μM | SANGER | ||
| SK-MEL-1 | Growth inhibition assay | Inhibition of human SK-MEL-1 cell growth in a cell viability assay, IC50=41.9927μM | SANGER | ||
| PC-3 | Growth inhibition assay | Inhibition of human PC-3 cell growth in a cell viability assay, IC50=42.2752μM | SANGER | ||
| KARPAS-299 | Growth inhibition assay | Inhibition of human KARPAS-299 cell growth in a cell viability assay, IC50=44.5948μM | SANGER | ||
| DBTRG-05MG | Growth inhibition assay | Inhibition of human DBTRG-05MG cell growth in a cell viability assay, IC50=44.6546μM | SANGER | ||
| HCC1806 | Growth inhibition assay | Inhibition of human HCC1806 cell growth in a cell viability assay, IC50=45.2169μM | SANGER | ||
| NCI-H2009 | Growth inhibition assay | Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50=45.2843μM | SANGER | ||
| HCC2157 | Growth inhibition assay | Inhibition of human HCC2157 cell growth in a cell viability assay, IC50=45.7976μM | SANGER | ||
| EM-2 | Growth inhibition assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50=47.4011μM | SANGER | ||
| DOK | Growth inhibition assay | Inhibition of human DOK cell growth in a cell viability assay, IC50=48.3877μM | SANGER | ||
| HepG2 | Function assay | Inhibition of cJun phosphorylation in HepG2 cell line, Ki=0.004μM | 16759099 | ||
| HepG2 | Function assay | Inhibition of cJun phosphorylation in HepG2 cell line, EC50=0.92μM | 16759099 | ||
| 點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | JNK Inhibitor VIII (TCS JNK 6o) 是一種 c-Jun N-terminal kinases 的抑制劑，對(duì)JNK-1和JNK-2的IC50值分別為45 nM和160 nM。JNK Inhibitor VIII (TCS JNK 6o) 可抑制JNK-1、JNK-2和JNK-3，對(duì)應(yīng)的Ki值分別為2 nM、4 nM和52 nM。 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點(diǎn) |
|
化學(xué)信息&溶解度
| 分子量 | 356.38 | 分子式 | C18H20N4O4 |
| CAS號(hào) | 894804-07-0 | SDF | -- |
| Smiles | CCOC1=C(C(=CC(=N1)NC(=O)CC2=C(C=CC(=C2)OC)OC)N)C#N | ||
| 儲(chǔ)存條件(自收到貨起) | 3年 -20°C 粉狀 | ||
|
體外溶解度 |
DMSO : 71 mg/mL ( (199.22 mM) ；DMSO吸濕會(huì)降低化合物溶解度，請(qǐng)使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計(jì)算器 |
|
體內(nèi)溶解度 現(xiàn)配現(xiàn)用，請(qǐng)按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動(dòng)物體內(nèi)配方計(jì)算器 | ||||
實(shí)驗(yàn)計(jì)算
摩爾濃度計(jì)算器
動(dòng)物體內(nèi)配方計(jì)算器（澄清溶液）
第一步：請(qǐng)輸入基本實(shí)驗(yàn)信息（考慮到實(shí)驗(yàn)過程中的損耗，建議多配一只動(dòng)物的藥量）
mg/kg
g
μL
只
第二步：請(qǐng)輸入動(dòng)物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請(qǐng)聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計(jì)算結(jié)果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請(qǐng)先聯(lián)系Selleck）；
體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進(jìn)行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術(shù)支持
在訂購(gòu)、運(yùn)輸、儲(chǔ)存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會(huì)在24小時(shí)內(nèi)盡快聯(lián)系您。
如果有其他問題，請(qǐng)給我們留言。
* 必填項(xiàng)
Tags: buy JNK Inhibitor VIII | JNK Inhibitor VIII supplier | purchase JNK Inhibitor VIII | JNK Inhibitor VIII cost | JNK Inhibitor VIII manufacturer | order JNK Inhibitor VIII | JNK Inhibitor VIII distributor
Copyright 2013 Selleck中國(guó). All Rights Reserved.
滬ICP備13045345號(hào)-1滬公網(wǎng)安備 31011502012800號(hào)
